Could Clearing “Zombie” Cells Help Aging Skin Heal Like It Used To?

Key takeaways

• Applying the experimental senolytic ABT-263 to the skin of older mice for five days reduced markers of cellular senescence before injury.

• After subsequent wounding, 80% of treated mice had fully healed by day 24, compared with 56% of untreated older mice.

• The treatment was associated with a short-lived inflammatory response followed by greater activity in pathways related to collagen production and new blood-vessel formation.

• This is a preclinical experiment, not a skincare finding. ABT-263 has not been established as safe or effective as a topical treatment in people.

Older skin does not only show its age in fine lines or texture changes. It also loses some of its ability to recover: wounds close more slowly, collagen rebuilding becomes less coordinated, and the local response to injury can become less effective.

This study starts with a potential contributor to that decline—senescent cells. These are cells that have exited the normal cycle of division after stress or damage but remain metabolically active in tissue. Rather than disappearing, they can release signals that alter the behavior of nearby cells and interfere with repair.

The researchers asked a straightforward question: if some of those cells are cleared from older skin before an injury, is the tissue better positioned to heal?

A local senolytic test

The intervention was ABT-263, also called navitoclax, an experimental drug classed as a senolytic because it can preferentially eliminate senescent cells. Instead of systemic dosing, researchers applied it topically to aged mouse skin for five days.

That local delivery is central to the concept. Senolytics are often discussed as whole-body interventions, but topical use could theoretically direct exposure to a specific tissue while limiting the rest of the body’s exposure. That remains a hypothesis, though—not a demonstrated safety advantage in humans.

After the five-day pre-treatment, the scientists created small wounds and followed healing. By day 24, complete wound closure occurred in 80% of treated mice versus 56% of untreated older mice.

Inflammation is not always the enemy

One of the more interesting findings is that treatment briefly increased inflammation in the skin. That may sound counterintuitive, particularly in a longevity context where chronic inflammation is often a target for reduction.

But wound repair requires a well-timed inflammatory phase. Immune cells first clear debris and coordinate the response; then rebuilding begins. The problem is not inflammation in every form. It is inflammation that is persistent, mistimed, or unresolved.

In this case, the short-term inflammatory signal appeared alongside increased activity in genes tied to collagen production and angiogenesis—the formation of new blood vessels needed to deliver oxygen and nutrients to rebuilding tissue.

The preconditioning idea

The study is best understood as preconditioning, not treatment after a wound has already occurred. The authors cleared senescent cells first, then injured the skin.

That matters because it suggests senescent cells may leave aging tissue less prepared to mount a coordinated repair response. Removing some of that cellular burden may create a more responsive environment before the demand for repair arrives.

The finding was also more pronounced in older mice than younger mice, which is biologically plausible: aged tissue contains more senescent cells to target in the first place.

A longevity lens

This study gives a tangible version of a bigger senolytic hypothesis: cellular senescence may matter not only because of its association with aging, but because it can impair the practical functions that determine resilience—healing, regeneration, and recovery after stress.

The key word is may. Senescent cells are not uniformly harmful; they also participate in normal biological processes, including some aspects of wound repair. The goal, if this approach ever translates, would not be indiscriminate cell clearing. It would be precise timing, appropriate dose, and tissue-specific targeting.

The takeaway

Topical ABT-263 helped older mice clear senescence markers and heal wounds faster, while activating a repair program involving inflammation, collagen, and blood-vessel growth.

It is an appealing proof of concept for localized senolytics, but far from a consumer skincare claim. The important signal is that improving aged skin may eventually mean more than stimulating collagen at the surface—it may mean changing the cellular environment that determines whether repair can happen well at all.

Reference:
Shvedova M, Thanapaul RJR, Ha J, et al. Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing. Aging. 2024;17(1):16. doi:10.18632/aging.206165.